Prognostic value of preoperative serum immunosuppressive acidic protein in patients with esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 16, Issue 2, 2003, Pages 102-106

  Shimada, H ^a   Nabeya, Y ^a   Okazumi, S ^a   Matsubara, H ^a   Miyazawa, Y ^a   Shihratori, T ^a   Hayashi, H ^a   Aoki, T ^a   Sugaya, M ^a   Gunji, Y ^a   Kobayashi, S ^a   Ochiai, T ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE ACID PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PATHOLOGY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

AGED; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM PROTEINS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041562606     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.2003.00306.x     Document Type: Article

References (19)

1. Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein form ascitic fluids of cancer patients. Cancer Res 1981; 41: 3244-52.
2. Yamanaka N, Harabuchi Y, Himi T, Kataura A. Immunosuppressive substance in the sera of head and neck cancer patients. Cancer 1988; 62: 1293-8.
3. Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Surg Today 1993; 23: 669-74.
4. Shibata Y, Tamaura K, Ishida N. In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in connection with its high level in tumor bearing mice. Cancer Res 1983; 43: 2889-96.
5. Ogoshi K, Tajima T, Mitomi T, Tsuda M, Yamamura M. Acute-phase plasma proteins in gastric cancer: Association with metastatic potential and prognosis. Tumour Biol 1996; 17: 281-9.
6. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999; 162: 1934-7.
7. Miyata Y, Koga S, Nishikido M, et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001; 58: 161-4.
8. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 2000; 23: 263-6.
9. Maccio A, La P, Santona M C, Pagliara L, Melis G B, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlation with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998; 69: 248-52.
10. Shimada M, Takenaka K, Kawahara N, et al. Surgical treatment strategy for patients with stage IV hepatocellular carcinoma. Surgery 1996; 119: 517-22.
11. Kimura Y, Fujieda S, Takebayashi T, Tanaka T, Sugimoto C, Saito T. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Letter 2000; 155: 163-8.
12. Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y, Nakazato H. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Cancer 1996; 77: 2206-12.
13. Scambia G, Foti E, Ferrandina G, et al. Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. Am J Obstet Gynecol 1996; 175: 1606-10.
14. Daly J M, Karnell L H, Menck H R. National cancer database report on esophageal carcinoma. Cancer 1996; 78: 1820-8.
15. Isono K, Onoda S, Ishikawa T, Sato H, Nakayama K. Studies on the causes of deaths from esophageal carcinoma. Cancer 1982; 49: 2173-9.
16. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal cancer patients. Cancer 2001; 92: 663-9.
17. Shimada H, Takeda A, Nabeya Y, et al. Prognostic significance of serum thymidine phosphrylase in the patients with esophageal squamous cell carcinoma. Cancer 2002; 94: 1947-54.
18. Nabeya Y, Shimada H, Takeda A, et al. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a useful prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 2002; 94: 940-9.
19. Sobin L H, Wittekind C H. UICC TNM Classification of Malignant Tumors, 5th edn. John Wiley & Sons, Inc. 1997.